Kazan medical journalKazan medical journal0368-48142587-9359Eco-Vector237410.17750/KMJ2016-101Review ArticleModern concepts of celiac diseaseKopishinskayaS Vkopishinskaya@gmail.comNizhny Novgorod State Medical Academy1501201697110110728032016Copyright © 2016, Kopishinskaya S.V.2016Celiac disease is widespread autoimmune disease, which develops in genetically predisposed individuals in case of gluten intake and manifests as enteropathy and extraintestinal signs or without symptoms. Celiac disease is recognized as one of the most common genetic diseases in the world with about 1% prevalence. The review organizes literature data concerning epidemiology, pathogenesis, clinical presentation, diagnosis and treatment of celiac disease. The historical and geographical features of the celiac disease prevalence associated with the wheat consumption and human migration are described. The disease pathogenesis caused by both genetic factors, in particular the human leukocyte antigens (HLA) type, and the environmental influence, the gluten intake. The classification uniting a number of gluten-related diseases, which differ in the development mechanism and clinical manifestations, is described. Celiac disease can clinically manifest by classic and atypical symptoms or occur in a latent form. It usually manifests in early childhood after the introduction of the cereals into diet with symptoms of chronic diarrhea, delayed growth and development. Celiac disease develops throughout life and increases morbidity and mortality if left untreated. Diagnosis is based on the presence of antibodies to tissue transglutaminase, gliadin and deamidated peptides and biopsy results. An algorithm for the interpretation of the diagnostic findings in the celiac disease diagnosis is presented. Significance of gluten-free diet and new drugs in the celiac disease treatment is highlighted. Different ways to reduce the gluten toxicity for celiac patients are described, such as gliadin hydrolysis modification, gluten intake decrease, immune response activity inhibition.celiac diseaseglutenpolyneuropathyataxiagluten-free dietцелиакияглютенполиневропатияатаксиябезглютеновая диета[Копишинская С.В., Густов А.В., Репин А.А., Светозарский С.Н. Висцеральная боль. Мед. альманах. 2013; (1): 116-120.][Костарева Т.Ю., Афраймович М.Г., Азовцева И.А., Васильева О.Е. Целиакия - трудный диагноз для педиатра на современном этапе. Мед. альманах. 2010; (2): 110-113.][Рахимова Г.М., Исмагилова М.И. Случай целиакии у девочки 2 лет. Казанский мед. ж. 2007; 88 (3): 274-275.][Саковец Т.Г., Богданов Э.И. Гипокалиемические миоплегии. Казанский мед. ж. 2013; 94 (6): 933-938.][Capozzi A., Vincentini O., Gizzi P. et al. Modulatory effect of Gliadin Peptide 10-mer on epithelial intestinal CACO-2 cell inflammatory response. PLoS One. 2013; 8 (6): e66561. http://dx.doi.org/10.1371/journal.pone.0066561][Cataldo F., Pitarresi N., Accomando S., Greco L. Epidemiological and clinical features in immigrant children with coeliac disease: an Italian multicentre study. Dig. Liver Dis. 2004; 36: 722-729. http://dx.doi.org/10.1016/j.dld.2004.03.021][Cataldo F., Montalto G. Celiac disease in the developing countries: a new and challenging public health problem. World J. Gastroenterol. 2007; 13: 2153-2159. http://dx.doi.org/10.3748/wjg.v13.i15.2153][Catassi C., Fabiani E., Iacono G. et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am. J. Clin. Nutr. 2007; 85: 160-166.][Catassi C., Yachha S.K. The global village of celiac disease. Frontiers in celiac disease. Eds. Fasano A., Troncone R., Branski D. Basel: Switzerland Karger. 2008; 23-31. http://dx.doi.org/10.1159/000128610][Corrao G., Corazza G.R., Bagnardi V. et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 2001; 358: 356-361. http://dx.doi.org/10.1016/S0140-6736(01)05554-4][Dawood F.H., Jabbar A.A., Al-Mudaris A.F., Al-Hasani M.H. Association of HLA antigens with coeliac disease among Iraqi children. Tissue Antigens. 1981; 18: 35-39. http://dx.doi.org/10.1111/j.1399-0039.1981.tb01358.x][De Angelis M., Rizzello C.G., Fasano A. et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim. Biophys. Acta. 2006; 1762: 80-93.][Erkan T., Kutlu T., Yilmaz E. et al. Human leukocyte antigens in Turkish pediatric celiac patients. Turk. J. Pediatr. 1999; 41: 181-188.][Fasano A., Berti I., Gerarduzzi T. et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: an evolving spectrum. Gastroenterology. 2001; 120: 636-651. http://dx.doi.org/10.1053/gast.2001.22123][Fasano A. Novel therapeutic/integrative approaches for celiac disease and dermatitis herpetiformis. Clin. Dev. Immunol. 2012; 2012: 959061. http://dx.doi.org/10.1155/2012/959061][Freeman H.J. Neurological disorders in adult celiac disease. Can. J. Gastroenterol. 2008; 22 (11): 909-911.][Freeman H.J. Risk factors in familial forms of celiac disease. World J. Gastroenterol. 2010; 16: 1828-1831. http://dx.doi.org/10.3748/wjg.v16.i15.1828][Gujral N., Freeman H.J., Thomson A.B.R. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J. Gastroenterol. 2012; 18 (42): 6036-6059. http://dx.doi.org/10.3748/wjg.v18.i42.6036][Gujral N., Löbenberg R., Suresh M., Sunwoo H. In vitro and in vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. J. Agric. Food Chem. 2012; 60: 3166-3172. http://dx.doi.org/10.1021/jf205319s][Haines M.L., Anderson R.P., Gibson P.R. Systematic review: The evidence base for long-term management of coeliac disease. Aliment. Pharmacol. Ther. 2008; 28: 1042-1066. http://dx.doi.org/10.1111/j.1365-2036.2008.03820.x][Heap G.A., van Heel D.A. Genetics and pathogenesis of coeliac disease. Semin. Immunol. 2009; 21: 346-354. http://dx.doi.org/10.1016/j.smim.2009.04.001][Jabbar A.A. HLA and disease associations in Iraq. Dis. Markers. 1993; 11: 161-170. http://dx.doi.org/10.1155/1993/192019][Karell K., Louka A.S., Moodie S.J. et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum. Immunol. 2003; 64: 469-477. http://dx.doi.org/10.1016/S0198-8859(03)00027-2][Kelly C.P., Green P.H., Murray J.A. Intestinal permeability of larazotide acetate in celiac disease: results of a phase IIB 6-week gluten-challenge clinical trial (abstr). Gastroenterology. 2009; 136: A-474. http://dx.doi.org/10.1016/S0016-5085(09)62182-X][Kneepkens C.M.F, von Blomberg B.M.E. Coeliac disease. Eur. J. Pediatr. 2012; 171: 1011-1021. http://dx.doi.org/10.1007/s00431-012-1714-8][Larsson K., Carlsson A., Cederwall E. et al. Annual screening detects celiac disease in children with type 1 diabetes. Pediatr. Diabetes. 2008; 9: 354-359. http://dx.doi.org/10.1111/j.1399-5448.2008.00367.x][Lee H.J., Anderson Z., Ryu D. Gluten contamination in foods labeled as «gluten free» in the United States. J. Food Prot. 2014; 77 (10): 1830-1833. http://dx.doi.org/10.4315/0362-028X.JFP-14-149][Leffler D.A., Kelly C.P., Green P.H. et al. Larazotide Acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015 Feb. 12; pii: S0016-5085(15): 00199-7.][Liang L., Pinier M., Leroux J.C., Subirade M. Interaction of alpha-gliadin with poly(HEMA-co-SS): structural characterization and biological implication. Biopolymers. 2009; 91: 169-178. http://dx.doi.org/10.1002/bip.21109][Ludvigsson J.F., Bai J.C., Biagi F. et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014; 63: 1210-1228. http://dx.doi.org/10.1136/gutjnl-2013-306578][Makharia G.K. Current and emerging therapy for celiac disease. Front. Med. (Lausanne). 2014; 1: 6. http://dx.doi.org/10.3389/fmed.2014.00006][Mäki M., Mustalahti K., Kokkonen J. et al. Prevalence of Celiac disease among children in Finland. N. Engl. J. Med. 2003; 348: 2517-2524. http://dx.doi.org/10.1056/NEJMoa021687][Matysiak-Budnik T., Candalh C., Cellier C. et al. Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology. 2005; 129: 786-796. http://dx.doi.org/10.1053/j.gastro.2005.06.016][Meeuwisse G.W. Diagnostic criteria in CD. Acta Paediatr. Scand. 1970; 59: 461-463.][Megiorni F., Mora B., Bonamico M. et al. HLA-DQ and risk gradient for celiac disease. Hum. Immunol. 2009; 70: 55-59. http://dx.doi.org/10.1016/j.humimm.2008.10.018][Mooney P.D., Hadjivassiliou M., Sanders D.S. Coeliac disease. BMJ. 2014; 348: g1561.][Nisticò L., Fagnani C., Coto I. et al. Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut. 2006; 55: 803-808. http://dx.doi.org/10.1136/gut.2005.083964][Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch. Dis. Child. 1990; 65: 909-911. http://dx.doi.org/10.1136/adc.65.8.909][Rostami K., Kerckhaert J., Tiemessen R. et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am. J. Gastroenterol. 1999; 94: 888-894. http://dx.doi.org/10.1111/j.1572-0241.1999.983_f.x][Rostom A., Murray J.A., Kagnoff M.F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology. 2006; 131: 1981-2002. http://dx.doi.org/10.1053/j.gastro.2006.10.004][Sapone A., Bai J.C., Ciacci C. et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Medicine. 2012; 10: 13. http://dx.doi.org/10.1186/1741-7015-10-13][Stepniak D., Koning F. Celiac disease--sandwiched between innate and adaptive immunity. Hum. Immunol. 2006; 67: 460-468. http://dx.doi.org/10.1016/j.humimm.2006.03.011][Thomas H.J., Ahmad T., Rajaguru C. et al. Contribution of histological, serological, and genetic factors to the clinical heterogeneity of adult-onset coeliac disease. Scand. J. Gastroenterol. 2009; 44: 1076-1083. http://dx.doi.org/10.1080/00365520903100473][Tye-Din J.A., Anderson R.P., Ffrench R.A. et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin. Immunol. 2010;134: 289-295. http://dx.doi.org/10.1016/j.clim.2009.11.001]